2 Mar 2020 17:29
Sensyne Health Appoints Interim Chief Financial Officer
Oxford, UK; 02 March 2020: Sensyne Health plc (LSE:SENS) ("Sensyne" or "the Company"), the British Clinical AI technology company, today announces that it has appointed Michael Norris as Interim Chief Financial Officer, with immediate effect.
Michael has more than 20 years' experience working with public and private companies in the technology and life sciences sectors and has overseen a wide range of corporate activities. Michael has a wealth of CFO experience, serving as CFO and Interim CFO for a number of companies including Beckley Canopy Therapeutics, Itaconix, HMR and Rapid Rhythm. Michael is a Fellow of the Chartered Institute of Management Accountants.
A search for a permanent CFO is ongoing and the Company will update the market in due course.
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson, Chief Executive Officer | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+ 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Oliver Jackson | |
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma | |
Euan Brown | |
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Mary-Jane Elliott | |
Sukaina Virji | |
Melissa Gardiner | |
sensynehealth@consilium-comms.com |
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com www.sensynehealth.com.